Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone-Refractory Prostate Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT04232761
What this trial is testing

Study to Gather Information on the Safety and How Radium-223 Dichloride, an Alpha Particle-emitting Radioactive Agent, Works Under Routine Clinical Practice in Taiwan in Patients With Castration-resistant Prostate Cancer (CRPC) Which Has Spread to the Bone

Who this might be right for
Castration-resistant Prostate Cancer
Bayer 194
Testing effectiveness (Phase 2)Ended earlyNCT01313559
What this trial is testing

Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer

Who this might be right for
Castrate Resistant Prostate CancerChemotherapy Naive Prostate CancerProstate Cancer
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University 6
Early research (Phase 1)Looking for participantsNCT04886986
What this trial is testing

Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Weill Medical College of Cornell University 42
Early research (Phase 1)Ended earlyNCT02500901
What this trial is testing

Enzalutamide and Niraparib in the Treatment of Metastatic Castrate-Resistant Prostate Cancer (CRPC)

Who this might be right for
Metastatic Prostate Cancer
Paul Mathew, MD 2
Early research (Phase 1)Looking for participantsNCT05942001
What this trial is testing

Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Who this might be right for
Advanced Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd. 100
Early research (Phase 1)Study completedNCT00868595
What this trial is testing

MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer

Who this might be right for
Castrate Resistant Prostate Cancer (CRPC)
Bellicum Pharmaceuticals 18
Testing effectiveness (Phase 2)Study completedNCT02077634
What this trial is testing

Trial of Abiraterone Acetate Plus LHRH-therapy Versus Abiraterone Acetate Sparing LHRH-therapy in Patients With Progressive Chemotherapy-naïve Castration-resistant Prostate Cancer (SPARE)

Who this might be right for
Prostate Cancer
Universität des Saarlandes 68
Testing effectiveness (Phase 2)Study completedNCT00849121
What this trial is testing

Two-Arm Study of a DNA Vaccine Encoding Prostatic Acid Phosphatase (PAP) in Patients With Non-Metastatic Castrate-Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
University of Wisconsin, Madison 17
Early research (Phase 1)Study completedNCT05585034
What this trial is testing

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

Who this might be right for
Head and Neck Squamous Cell CarcinomaMelanoma Excluding Uveal MelanomaNon-small Cell Lung Cancer, Squamous or Non-squamous+6 more
Xencor, Inc. 60
Early research (Phase 1)Active Not RecruitingNCT06229366
What this trial is testing

[Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Prostate CancerMetastatic Castration-resistant Prostate CancerOligometastatic Prostate Carcinoma+1 more
Eli Lilly and Company 142
Testing effectiveness (Phase 2)Study completedNCT01511536
What this trial is testing

Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Sanofi 38
Testing effectiveness (Phase 2)Study completedNCT01051570
What this trial is testing

Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel

Who this might be right for
Prostate Cancer
Barbara Ann Karmanos Cancer Institute 26
Testing effectiveness (Phase 2)Study completedNCT01503229
What this trial is testing

Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Who this might be right for
Hormone-Resistant Prostate CancerMetastatic Prostate CarcinomaRecurrent Prostate Carcinoma+1 more
University of Washington 32
Testing effectiveness (Phase 2)Active Not RecruitingNCT04592237
What this trial is testing

Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

Who this might be right for
Aggressive Variant Prostate CarcinomaCastration-Resistant Prostate CarcinomaMetastatic Prostate Carcinoma+3 more
M.D. Anderson Cancer Center 120
Testing effectiveness (Phase 2)Study completedNCT03643107
What this trial is testing

Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer Patients
Allarity Therapeutics 15
Not applicableWithdrawnNCT01692483
What this trial is testing

Post-marketing Surveillance Study on the Safety and Effectiveness of Abiraterone Acetate Among Adult Filipino Male Patients With Advanced Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Prostate Neoplasms
Janssen Pharmaceutica
Testing effectiveness (Phase 2)Study completedNCT04060394
What this trial is testing

Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Laekna Limited 49
Testing effectiveness (Phase 2)Ended earlyNCT03741712
What this trial is testing

SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC

Who this might be right for
Prostate CancerCastration-resistant Prostate Cancer
Jiangsu HengRui Medicine Co., Ltd. 9
Not applicableStudy completedNCT06013475
What this trial is testing

An Observational Cohort Study to Describe and Compare the Use of Darolutamide, Enzalutamide and Apalutamide and How Well These Work in Men With Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) in Real World Settings

Who this might be right for
Non-metastatic Castration-resistant Prostate Cancer
Bayer 1,375
Testing effectiveness (Phase 2)Active Not RecruitingNCT04655365
What this trial is testing

Detecting Metastases by PyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer.

Who this might be right for
Prostate Cancer
CHU de Quebec-Universite Laval 50
Next Page